ArticleTheranostics2023
Protein phosphatase 2A-B55β mediated mitochondrial p-GPX4 dephosphorylation promoted sorafenib-induced ferroptosis in hepatocellular carcinoma via regulating p53 retrograde signaling.
Abstract read
In one paragraph
Article in Theranostics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Targeting the miR-19b/PPP2R5E axis enhances temozolomide response in glioblastoma via ROS-induced DNA damage.British journal of cancer · 2026Article
- Ferroptosis regulatory networks as therapeutic sensitizers in combination therapy for hepatocellular carcinoma (Review).Oncology letters · 2026Review
- Berberine suppresses colorectal cancer progression by inducing ferroptosis-mediated energy metabolism disorders.Journal of advanced research · 2026Article
- TAF1 aggravates ferroptosis by promoting the ubiquitin-mediated degradation of nuclear GPX4.Journal of Zhejiang University. Science. B · 2026Article
- Palmitoylated COX-2Journal of advanced research · 2026Article
- Post-translational modification in hepatocellular carcinoma resistance: molecular mechanisms and therapeutic targeting.Frontiers in immunology · 2026Review
- Post-Translational Modification Networks in Ferroptosis: Orchestrating Defense, Drug Resistance, and Therapeutic Opportunities in Hepatocellular Carcinoma.Journal of hepatocellular carcinoma · 2026Review
- Post-translational modifications in hepatocellular carcinoma: mechanisms and therapeutic potential.Medical oncology (Northwood, London, England) · 2025Review
- Molecular network of metabolic reprogramming and precision diagnosis and treatment of hepatocellular carcinoma.Biomarker research · 2025Review
- From mitochondrial dysregulation to ferroptosis: Exploring new strategies and challenges in radioimmunotherapy (Review).International journal of oncology · 2025Review
- Artemisinin and Its Derivatives from Molecular Mechanisms to Clinical Applications: New Horizons Beyond Antimalarials.International journal of molecular sciences · 2025Review
- p53-regulated non-apoptotic cell death pathways and their relevance in cancer and other diseases.Nature reviews. Molecular cell biology · 2025Review
- The Molecular Interplay Between p53-Mediated Ferroptosis and Non-Coding RNAs in Cancer.International journal of molecular sciences · 2025Review
- PP1A Modulates the Efficacy of Lenvatinib Plus ICIs Therapy by Inhibiting Ferroptosis in Hepatocellular Carcinoma.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- ELANE enhances KEAP1 protein stability and reduces NRF2-mediated ferroptosis inhibition in metabolic dysfunction-associated fatty liver disease.Cell death & disease · 2025Article
- Hsa_piR_016975 Is a Novel Target of Nanotherapy that Boosts Hepatoma Progression and Sorafenib Resistance by Abating Maspin/GPX4-Mediated Ferroptosis.Biomaterials research · 2025Article
- Mitochondrial Regulation of Ferroptosis in Cancer Cells.International journal of biological sciences · 2025Review
- Integration Approaches of UPLC-Q-Exactive Orbitrap-MS/MS, Network Pharmacology Molecular Docking, and Molecular Dynamics to Explore the Effective Constituents and Potential Mechanisms ofCurrent pharmaceutical design · 2025Article
- Targeting ferroptosis opens new avenues in gliomas.International journal of biological sciences · 2024Review
- Breaking the Barriers of Therapy Resistance: Harnessing Ferroptosis for Effective Hepatocellular Carcinoma Therapy.Journal of hepatocellular carcinoma · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Bo QianState Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics; National Innovation Platform for Industry-Education Integration in Vaccine Research; School of Public Health, Xiamen University, Xiamen, China.
Lin CheState Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics; National Innovation Platform for Industry-Education Integration in Vaccine Research; School of Public Health, Xiamen University, Xiamen, China.
Ze-Bang DuState Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics; National Innovation Platform for Industry-Education Integration in Vaccine Research; School of Public Health, Xiamen University, Xiamen, China.
Ni-Jun GuoState Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics; National Innovation Platform for Industry-Education Integration in Vaccine Research; School of Public Health, Xiamen University, Xiamen, China.
Xin-Mou WuState Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics; National Innovation Platform for Industry-Education Integration in Vaccine Research; School of Public Health, Xiamen University, Xiamen, China.
Lei YangState Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics; National Innovation Platform for Industry-Education Integration in Vaccine Research; School of Public Health, Xiamen University, Xiamen, China.
Zhao-Xuan ZhengState Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics; National Innovation Platform for Industry-Education Integration in Vaccine Research; School of Public Health, Xiamen University, Xiamen, China.
Yun-Lu GaoState Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics; National Innovation Platform for Industry-Education Integration in Vaccine Research; School of Public Health, Xiamen University, Xiamen, China.
Ming-Zhu WangState Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics; National Innovation Platform for Industry-Education Integration in Vaccine Research; School of Public Health, Xiamen University, Xiamen, China.
Xiao-Xuan ChenState Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics; National Innovation Platform for Industry-Education Integration in Vaccine Research; School of Public Health, Xiamen University, Xiamen, China.
Ling XuState Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics; National Innovation Platform for Industry-Education Integration in Vaccine Research; School of Public Health, Xiamen University, Xiamen, China.
Zi-Jian ZhouState Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics; National Innovation Platform for Industry-Education Integration in Vaccine Research; School of Public Health, Xiamen University, Xiamen, China.
Yu-Chun LinState Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics; National Innovation Platform for Industry-Education Integration in Vaccine Research; School of Public Health, Xiamen University, Xiamen, China.
Zhong-Ning LinState Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics; National Innovation Platform for Industry-Education Integration in Vaccine Research; School of Public Health, Xiamen University, Xiamen, China.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Carcinoma, HepatocellularFerroptosisLiver NeoplasmsPhospholipid Hydroperoxide Glutathione PeroxidaseProtein Phosphatase 2SorafenibAnimalsCell NucleusDown-RegulationDrug Resistance, NeoplasmHeterograftsHumansMiceMice, Inbred BALB CMice, NudeMitochondriaGPX4 protein, humanPhospholipid Hydroperoxide Glutathione PeroxidaseProtein Phosphatase 2SorafenibTP53 protein, humanTumor Suppressor Protein p53FerroptosisGlutathione peroxidase 4Hepatocellular carcinomaProtein phosphatase 2A-B55β subunitRetrograding p53 signal
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.